Tezepelumab

TEZSPIRE

Open Tezepelumab in the interactive console ↗

Pronunciation: tez-e-PEL-yoo-mab

Tezepelumab ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Tezepelumab ballicule

What it isMonoclonal antibody blocking thymic stromal lymphopoietin; severe asthma and chronic rhinosinusitis with nasal polyps.

Why this oneHitting the top of the cascade makes it the one severe-asthma biologic that works regardless of eosinophil count or allergic phenotype.

What limits itHypersensitivity and injection reactions occur; taper steroids gradually and never use it for acute bronchospasm.

Tezepelumab molecular structure (skeletal formula) — Molecular structure: Tezepelumab

FDA label

Read the full label on DailyMed ↗

FDA dosing	Population	Start	Target	Max
Severe asthma (add-on maintenance)	Aged 12 years and older	210 mg SC every 4 weeks	210 mg q4w	210 mg q4w
Inadequately controlled chronic rhinosinusitis with nasal polyps (add-on maintenance)	Aged 12 years and older	210 mg SC every 4 weeks	210 mg q4w	210 mg q4w

Renal Undefined

Hepatic Undefined

Instructions

SC injection into thigh or abdomen (upper arm only if given by HCP/caregiver)
Allow to reach room temperature (~60 min); do not shake
Rotate injection sites
Not for acute bronchospasm or status asthmaticus

Available strengths

inj 210 mg/1.9 mL

Cautions

Hypersensitivity reactions, including anaphylaxis
Do not discontinue corticosteroids abruptly on initiation
Treat pre-existing helminth infections before starting
Avoid live attenuated vaccines

Adverse reactions

Pharyngitis
Arthralgia
Back pain
Nasopharyngitis, upper respiratory tract infection, epistaxis, influenza (CRSwNP)
Injection site reactions

Pregnancy No human data; monoclonal antibody with greater placental transfer in third trimester

Lactation No data; IgG present in human milk in small amounts

Cost

Tezepelumab (TEZSPIRE)

Strength		#/mo	generic $/unit	CostPlus
210 mg/1.9 mL	inj	per unit		not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Tezepelumab is administered under clinical supervision and dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

NO BOXED WARNINGS

Principal riskHypersensitivity reactions; not a rescue for acute asthma

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4

Overdose danger1 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Legacy pregnancy categoryN/A (post-2015 labeling)

Defining liabilityHypersensitivity and uncertain helminth-infection response

Open Tezepelumab in the interactive console ↗